

# Patrik Brundin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8581385/patrik-brundin-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

163  
papers

21,639  
citations

77  
h-index

147  
g-index

177  
ext. papers

25,085  
ext. citations

10.4  
avg, IF

7.05  
L-index

#	Paper	IF	Citations
163	Parkinson disease. <i>Nature Reviews Disease Primers</i> , <b>2017</b> , 3, 17013	51.1	1700
162	Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. <i>Nature Medicine</i> , <b>2008</b> , 14, 501-3	50.5	1293
161	Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein. <i>Nature Reviews Neuroscience</i> , <b>2002</b> , 3, 932-42	13.5	901
160	The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg. <i>Neuron</i> , <b>2003</b> , 40, 427-46	13.9	790
159	αSynuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 715-25	15.9	616
158	Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. <i>Nature Neuroscience</i> , <b>1999</b> , 2, 1137-40	25.5	582
157	Prion-like transmission of protein aggregates in neurodegenerative diseases. <i>Nature Reviews Molecular Cell Biology</i> , <b>2010</b> , 11, 301-7	48.7	549
156	Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. <i>Neuron</i> , <b>2002</b> , 33, 849-60	13.9	506
155	Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). <i>New England Journal of Medicine</i> , <b>1992</b> , 327, 1556-63	59.2	494
154	A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. <i>Journal of Experimental Medicine</i> , <b>2008</b> , 205, 1869-77	16.6	437
153	Caspase signalling controls microglia activation and neurotoxicity. <i>Nature</i> , <b>2011</b> , 472, 319-24	50.4	406
152	Dyskinesias following neural transplantation in Parkinson's disease. <i>Nature Neuroscience</i> , <b>2002</b> , 5, 627-8	25.5	365
151	Transplantation of fetal dopamine neurons in Parkinson's disease: one-year clinical and neurophysiological observations in two patients with putaminal implants. <i>Annals of Neurology</i> , <b>1992</b> , 31, 155-65	9.4	323
150	Mechanisms of action of intracerebral neural implants: studies on nigral and striatal grafts to the lesioned striatum. <i>Trends in Neurosciences</i> , <b>1987</b> , 10, 509-516	13.3	290
149	Improving the survival of grafted dopaminergic neurons: a review over current approaches. <i>Cell Transplantation</i> , <b>2000</b> , 9, 179-95	4	287
148	Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. <i>Annals of Neurology</i> , <b>1992</b> , 31, 166-73	9.4	279
147	Neural transplantation for the treatment of Parkinson's disease. <i>Lancet Neurology</i> , <b>2003</b> , 2, 437-45	24.1	278

146	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. <i>Annals of Neurology</i> , <b>1997</b> , 42, 95-107	9.4	276
145	Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line. <i>Journal of Biological Chemistry</i> , <b>2002</b> , 277, 38884-94	5.4	260
144	Caspase inhibition reduces apoptosis and increases survival of nigral transplants. <i>Nature Medicine</i> , <b>1999</b> , 5, 97-100	50.5	258
143	Beyond the brain: widespread pathology in Huntington's disease. <i>Lancet Neurology, The</i> , <b>2009</b> , 8, 765-74	24.1	257
142	Monitoring of cell viability in suspensions of embryonic CNS tissue and its use as a criterion for intracerebral graft survival. <i>Brain Research</i> , <b>1985</b> , 331, 251-9	3.7	257
141	Research in motion: the enigma of Parkinson's disease pathology spread. <i>Nature Reviews Neuroscience</i> , <b>2008</b> , 9, 741-5	13.5	251
140	Parkinson's disease and alpha synuclein: is Parkinson's disease a prion-like disorder?. <i>Movement Disorders</i> , <b>2013</b> , 28, 31-40	7	249
139	Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. <i>Behavioural Brain Research</i> , <b>2005</b> , 162, 1-10	3.4	245
138	Reformation of long axon pathways in adult rat central nervous system by human forebrain neuroblasts. <i>Nature</i> , <b>1990</b> , 347, 556-8	50.4	237
137	Widespread transneuronal propagation of Bsynucleinopathy triggered in olfactory bulb mimics prodromal Parkinson's disease. <i>Journal of Experimental Medicine</i> , <b>2016</b> , 213, 1759-78	16.6	232
136	Acceleration of Bsynuclein aggregation by exosomes. <i>Journal of Biological Chemistry</i> , <b>2015</b> , 290, 2969-82	5.4	228
135	Orexin loss in Huntington's disease. <i>Human Molecular Genetics</i> , <b>2005</b> , 14, 39-47	5.6	222
134	In vivo release of dopa and dopamine from genetically engineered cells grafted to the denervated rat striatum. <i>Neuron</i> , <b>1990</b> , 5, 393-402	13.9	214
133	No evidence for new dopaminergic neurons in the adult mammalian substantia nigra. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2004</b> , 101, 10177-82	11.5	213
132	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. <i>Annals of Neurology</i> , <b>2000</b> , 48, 689-695	9.4	211
131	Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. <i>JAMA Neurology</i> , <b>2014</b> , 71, 83-7	17.2	205
130	Are synucleinopathies prion-like disorders?. <i>Lancet Neurology, The</i> , <b>2010</b> , 9, 1128-38	24.1	191
129	Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. <i>Human Molecular Genetics</i> , <b>2002</b> , 11, 2395-407	5.6	191

128	Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. <i>PLoS ONE</i> , <b>2012</b> , 7, e39465	3.7	186
127	Progressive degeneration of human mesencephalic neuron-derived cells triggered by dopamine-dependent oxidative stress is dependent on the mixed-lineage kinase pathway. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 6329-42	6.6	184
126	Extensive graft-derived dopaminergic innervation is maintained 24 years after transplantation in the degenerating parkinsonian brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2016</b> , 113, 6544-9	11.5	182
125	Transfer of human $\beta$ synuclein from the olfactory bulb to interconnected brain regions in mice. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 555-73	14.3	181
124	Alpha-synuclein transfers from neurons to oligodendrocytes. <i>Glia</i> , <b>2014</b> , 62, 387-98	9	170
123	Cell survival and clinical outcome following intrastriatal transplantation in Parkinson disease. <i>Journal of Neuropathology and Experimental Neurology</i> , <b>2001</b> , 60, 741-52	3.1	161
122	The adult human brain harbors multipotent perivascular mesenchymal stem cells. <i>PLoS ONE</i> , <b>2012</b> , 7, e35577	3.7	159
121	Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. <i>Movement Disorders</i> , <b>2010</b> , 25, 1091-6	7	157
120	Critical issues of clinical human embryonic stem cell therapy for brain repair. <i>Trends in Neurosciences</i> , <b>2008</b> , 31, 146-53	13.3	157
119	Prying into the Prion Hypothesis for Parkinson's Disease. <i>Journal of Neuroscience</i> , <b>2017</b> , 37, 9808-9818	6.6	153
118	The use of the R6 transgenic mouse models of Huntington's disease in attempts to develop novel therapeutic strategies. <i>NeuroRx</i> , <b>2005</b> , 2, 447-64		151
117	Inflammation and $\beta$ synuclein's prion-like behavior in Parkinson's disease--is there a link?. <i>Molecular Neurobiology</i> , <b>2013</b> , 47, 561-74	6.2	148
116	Reduced hippocampal neurogenesis in R6/2 transgenic Huntington's disease mice. <i>Neurobiology of Disease</i> , <b>2005</b> , 20, 744-51	7.5	148
115	Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. <i>Neurology</i> , <b>2019</b> , 92, 329-337	6.5	144
114	Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease. <i>Human Molecular Genetics</i> , <b>2011</b> , 20, 2225-37	5.6	144
113	Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. <i>Clinics in Geriatric Medicine</i> , <b>2020</b> , 36, 1-12	3.8	143
112	Triggers, Facilitators, and Aggravators: Redefining Parkinson's Disease Pathogenesis. <i>Trends in Neurosciences</i> , <b>2019</b> , 42, 4-13	13.3	138
111	The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. <i>Neurobiology of Disease</i> , <b>2018</b> , 109, 226-248	7.5	136

110	Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. <i>Stem Cells</i> , <b>2012</b> , 30, 2054-62	5.8	136
109	Overexpressing Cu/Zn superoxide dismutase enhances survival of transplanted neurons in a rat model of Parkinson's disease. <i>Nature Medicine</i> , <b>1995</b> , 1, 226-31	50.5	136
108	The vermiform appendix impacts the risk of developing Parkinson's disease. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	135
107	Therapeutic approaches to target alpha-synuclein pathology. <i>Experimental Neurology</i> , <b>2017</b> , 298, 225-235	5.7	133
106	Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. <i>European Journal of Neuroscience</i> , <b>2001</b> , 14, 1492-504	3.5	117
105	The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. <i>Human Molecular Genetics</i> , <b>2005</b> , 14, 565-74	5.6	116
104	Neurogenin2 directs granule neuroblast production and amplification while NeuroD1 specifies neuronal fate during hippocampal neurogenesis. <i>PLoS ONE</i> , <b>2009</b> , 4, e4779	3.7	113
103	Biomarker-driven phenotyping in Parkinson's disease: A translational missing link in disease-modifying clinical trials. <i>Movement Disorders</i> , <b>2017</b> , 32, 319-324	7	111
102	Progressive alterations in the hypothalamic-pituitary-adrenal axis in the R6/2 transgenic mouse model of Huntington's disease. <i>Human Molecular Genetics</i> , <b>2006</b> , 15, 1713-21	5.6	110
101	Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. <i>Brain Research</i> , <b>2003</b> , 970, 47-57	3.7	106
100	Increased metabolism in the R6/2 mouse model of Huntington's disease. <i>Neurobiology of Disease</i> , <b>2008</b> , 29, 41-51	7.5	105
99	Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. <i>Movement Disorders</i> , <b>2020</b> , 35, 711-715	7	104
98	Precision medicine for disease modification in Parkinson disease. <i>Nature Reviews Neurology</i> , <b>2017</b> , 13, 119-126	15	103
97	Targeted Therapies for Parkinson's Disease: From Genetics to the Clinic. <i>Movement Disorders</i> , <b>2018</b> , 33, 684-696	7	101
96	Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson's disease. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 368ra174	17.5	99
95	Spread of aggregates after olfactory bulb injection of $\beta$ synuclein fibrils is associated with early neuronal loss and is reduced long term. <i>Acta Neuropathologica</i> , <b>2018</b> , 135, 65-83	14.3	98
94	Neural grafting in Parkinson's disease Problems and possibilities. <i>Progress in Brain Research</i> , <b>2010</b> , 184, 265-94	2.9	97
93	$\beta$ Synuclein: the long distance runner. <i>Brain Pathology</i> , <b>2013</b> , 23, 350-7	6	93

92	The concept of alpha-synuclein as a prion-like protein: ten years after. <i>Cell and Tissue Research</i> , <b>2018</b> , 373, 161-173	4.2	85
91	Survival, growth and function of dopaminergic neurons grafted to the brain. <i>Progress in Brain Research</i> , <b>1987</b> , 71, 293-308	2.9	85
90	Can Parkinson's disease pathology be propagated from one neuron to another?. <i>Progress in Neurobiology</i> , <b>2012</b> , 97, 205-19	10.9	83
89	Membrane interaction of $\beta$ synuclein in different aggregation states. <i>Journal of Parkinson's Disease</i> , <b>2011</b> , 1, 359-71	5.3	81
88	Signs of degeneration in 12-22-year old grafts of mesencephalic dopamine neurons in patients with Parkinson's disease. <i>Journal of Parkinson's Disease</i> , <b>2011</b> , 1, 83-92	5.3	79
87	Alpha-synuclein propagation: New insights from animal models. <i>Movement Disorders</i> , <b>2016</b> , 31, 161-8	7	79
86	Effects of cool storage on survival and function of intrastriatal ventral mesencephalic grafts. <i>Restorative Neurology and Neuroscience</i> , <b>1991</b> , 2, 123-35	2.8	76
85	Gut feelings about smoking and coffee in Parkinson's disease. <i>Movement Disorders</i> , <b>2014</b> , 29, 976-9	7	72
84	Microglia affect $\beta$ synuclein cell-to-cell transfer in a mouse model of Parkinson's disease. <i>Molecular Neurodegeneration</i> , <b>2019</b> , 14, 34	19	71
83	Sequential intracerebral transplantation of allogeneic and syngeneic fetal dopamine-rich neuronal tissue in adult rats: will the first graft be rejected?. <i>Cell Transplantation</i> , <b>1993</b> , 2, 307-17	4	69
82	Adsorption of $\beta$ synuclein to supported lipid bilayers: positioning and role of electrostatics. <i>ACS Chemical Neuroscience</i> , <b>2013</b> , 4, 1339-51	5.7	65
81	A cell culture model for monitoring $\beta$ synuclein cell-to-cell transfer. <i>Neurobiology of Disease</i> , <b>2015</b> , 77, 266-75	7.5	60
80	Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?. <i>Neurology</i> , <b>2020</b> , 94, 481-494	6.5	60
79	Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson's disease. <i>Neurobiology of Disease</i> , <b>2015</b> , 73, 70-82	7.5	59
78	Is COVID-19 a Perfect Storm for Parkinson's Disease?. <i>Trends in Neurosciences</i> , <b>2020</b> , 43, 931-933	13.3	58
77	Immunotherapy in Parkinson's Disease: Micromanaging Alpha-Synuclein Aggregation. <i>Journal of Parkinson's Disease</i> , <b>2015</b> , 5, 413-24	5.3	55
76	What's to like about the prion-like hypothesis for the spreading of aggregated $\beta$ synuclein in Parkinson disease?. <i>Prion</i> , <b>2013</b> , 7, 92-7	2.3	53
75	Sorting out release, uptake and processing of alpha-synuclein during prion-like spread of pathology. <i>Journal of Neurochemistry</i> , <b>2016</b> , 139 Suppl 1, 275-289	6	53

74	The role of Galectin-3 in $\beta$ -synuclein-induced microglial activation. <i>Acta Neuropathologica Communications</i> , <b>2014</b> , 2, 156	7.3	48
73	How strong is the evidence that Parkinson's disease is a prion disorder?. <i>Current Opinion in Neurology</i> , <b>2016</b> , 29, 459-66	7.1	48
72	Are Stem Cell-Based Therapies for Parkinson's Disease Ready for the Clinic in 2016?. <i>Journal of Parkinson's Disease</i> , <b>2016</b> , 6, 57-63	5.3	47
71	Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. <i>Journal of Neurochemistry</i> , <b>2001</b> , 78, 694-703	6	45
70	Spreading of $\beta$ -synuclein in the face of axonal transport deficits in Parkinson's disease: a speculative synthesis. <i>Neurobiology of Disease</i> , <b>2015</b> , 77, 276-83	7.5	43
69	Prion-like propagation of pathology in Parkinson disease. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2018</b> , 153, 321-335	3	42
68	Enrichment of risk SNPs in regulatory regions implicate diverse tissues in Parkinson's disease etiology. <i>Scientific Reports</i> , <b>2016</b> , 6, 30509	4.9	42
67	$\beta$ -synuclein conformational strains spread, seed and target neuronal cells differentially after injection into the olfactory bulb. <i>Acta Neuropathologica Communications</i> , <b>2019</b> , 7, 221	7.3	41
66	Neuropathology in transplants in Parkinson's disease: implications for disease pathogenesis and the future of cell therapy. <i>Progress in Brain Research</i> , <b>2012</b> , 200, 221-41	2.9	39
65	Neural connectivity predicts spreading of alpha-synuclein pathology in fibril-injected mouse models: Involvement of retrograde and anterograde axonal propagation. <i>Neurobiology of Disease</i> , <b>2020</b> , 134, 104623	7.5	38
64	Survival of expanded dopaminergic precursors is critical for clinical trials. <i>Nature Neuroscience</i> , <b>1998</b> , 1, 537	25.5	36
63	Can infections trigger alpha-synucleinopathies?. <i>Progress in Molecular Biology and Translational Science</i> , <b>2019</b> , 168, 299-322	4	35
62	Quinolinic acid-induced inflammation in the striatum does not impair the survival of neural allografts in the rat. <i>European Journal of Neuroscience</i> , <b>1998</b> , 10, 2595-606	3.5	35
61	Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. <i>Molecular Neurodegeneration</i> , <b>2018</b> , 13, 28	19	34
60	Lewy body pathology in long-term fetal nigral transplants: is Parkinson's disease transmitted from one neural system to another?. <i>Neuropsychopharmacology</i> , <b>2009</b> , 34, 254	8.7	34
59	Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. <i>European Journal of Neuroscience</i> , <b>2001</b> , 14, 1425-35	3.5	34
58	Differential effects of Bcl-2 overexpression on fibre outgrowth and survival of embryonic dopaminergic neurons in intracerebral transplants. <i>European Journal of Neuroscience</i> , <b>1999</b> , 11, 3073-81	3.5	34
57	A Proposed Roadmap for Parkinson's Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 31-61	5.3	33

56	Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatments. <i>Journal of Parkinson's Disease</i> , <b>2013</b> , 3, 231-9	5.3	32
55	Biochemical Profiling of the Brain and Blood Metabolome in a Mouse Model of Prodromal Parkinson's Disease Reveals Distinct Metabolic Profiles. <i>Journal of Proteome Research</i> , <b>2018</b> , 17, 2460-2469	5.6	32
54	Novel animal model defines genetic contributions for neuron-to-neuron transfer of $\alpha$ -synuclein. <i>Scientific Reports</i> , <b>2017</b> , 7, 7506	4.9	27
53	Nilotinib - Differentiating the Hope from the Hype. <i>Journal of Parkinson's Disease</i> , <b>2016</b> , 6, 519-22	5.3	27
52	NGF rescues hippocampal cholinergic neuronal markers, restores neurogenesis, and improves the spatial working memory in a mouse model of Huntington's Disease. <i>Journal of Huntington's Disease</i> , <b>2013</b> , 2, 69-82	1.9	26
51	Tryptophan Metabolites Are Associated With Symptoms and Nigral Pathology in Parkinson's Disease. <i>Movement Disorders</i> , <b>2020</b> , 35, 2028-2037	7	25
50	Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. <i>Movement Disorders Clinical Practice</i> , <b>2020</b> , 7, 357-360	2.2	24
49	New Frontiers in Parkinson's Disease: From Genetics to the Clinic. <i>Journal of Neuroscience</i> , <b>2018</b> , 38, 9375-9382	6.3	24
48	Endogenous alpha-synuclein monomers, oligomers and resulting pathology: let's talk about the lipids in the room. <i>Npj Parkinson's Disease</i> , <b>2019</b> , 5, 23	9.7	23
47	Gut Microbiota Dysbiosis Is Associated with Elevated Bile Acids in Parkinson's Disease. <i>Metabolites</i> , <b>2021</b> , 11,	5.6	23
46	Is Exenatide a Treatment for Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 451-458	5.3	22
45	Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson's Disease. <i>Metabolites</i> , <b>2018</b> , 8,	5.6	22
44	Addition of Lateral Ganglionic Eminence to Rat Mesencephalic Grafts Affects Fiber Outgrowth but Does not Enhance Function. <i>Cell Transplantation</i> , <b>1997</b> , 6, 277-286	4	17
43	Basic science breaks through: New therapeutic advances in Parkinson's disease. <i>Movement Disorders</i> , <b>2015</b> , 30, 1521-7	7	16
42	Is the Enzyme ACMSD a Novel Therapeutic Target in Parkinson's Disease?. <i>Journal of Parkinson's Disease</i> , <b>2017</b> , 7, 577-587	5.3	15
41	The Linked Clinical Trials initiative (LCT) for Parkinson's disease. <i>European Journal of Neuroscience</i> , <b>2019</b> , 49, 307-315	3.5	12
40	Parkinson disease: Laying the foundations for disease-modifying therapies in PD. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 553-5	15	10
39	Deficits in olfactory sensitivity in a mouse model of Parkinson's disease revealed by plethysmography of odor-evoked sniffing. <i>Scientific Reports</i> , <b>2020</b> , 10, 9242	4.9	10



38	Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. <i>Neurology</i> , <b>2018</b> , 90, 74-82	6.5	10
37	Recent Advances in the Development of Stem-Cell-Derived Dopaminergic Neuronal Transplant Therapies for Parkinson's Disease. <i>Movement Disorders</i> , <b>2021</b> , 36, 1772-1780	7	8
36	Cancer enzyme affects Parkinson's disease. <i>Science</i> , <b>2018</b> , 362, 521-522	33.3	8
35	Solving the conundrum of insoluble protein aggregates. <i>Lancet Neurology, The</i> , <b>2017</b> , 16, 258-259	24.1	7
34	CuZn superoxide dismutase transgenic retinal transplants. <i>Graefers Archive for Clinical and Experimental Ophthalmology</i> , <b>1999</b> , 237, 336-41	3.8	7
33	Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal. <i>Translational Neurodegeneration</i> , <b>2020</b> , 9, 39	10.3	7
32	Mitomycin-C treatment during differentiation of induced pluripotent stem cell-derived dopamine neurons reduces proliferation without compromising survival or function in vivo. <i>Stem Cells Translational Medicine</i> , <b>2021</b> , 10, 278-290	6.9	7
31	Loss of One Engrailed1 Allele Enhances Induced $\beta$ Synucleinopathy. <i>Journal of Parkinson's Disease</i> , <b>2019</b> , 9, 315-326	5.3	6
30	Nilotinib in Patients with Advanced Parkinson's Disease: A Randomized Phase 2A Study (NILO-PD)		6
29	Perturbation of in vivo Neural Activity Following $\beta$ Synuclein Seeding in the Olfactory Bulb. <i>Journal of Parkinson's Disease</i> , <b>2020</b> , 10, 1411-1427	5.3	5
28	Important Aspects of Surgical Methodology for Transplantation in Parkinson's Disease <b>2006</b> , 131-165		5
27	Novel approaches to counter protein aggregation pathology in Parkinson's disease. <i>Progress in Brain Research</i> , <b>2020</b> , 252, 451-492	2.9	4
26	Is exenatide the next big thing in Parkinson's disease?. <i>Journal of Parkinson's Disease</i> , <b>2014</b> , 4, 345-7	5.3	4
25	Drug Repurposing for Parkinson's Disease: The International Linked Clinical Trials experience. <i>Frontiers in Neuroscience</i> , <b>2021</b> , 15, 653377	5.1	4
24	Fire prevention in the Parkinson's disease brain. <i>Nature Medicine</i> , <b>2018</b> , 24, 900-902	50.5	3
23	Upregulation of $\beta$ Synuclein following immune activation: Possible trigger of Parkinson's disease.. <i>Neurobiology of Disease</i> , <b>2022</b> , 166, 105654	7.5	3
22	Digesting recent findings: gut alpha-synuclein, microbiome changes in Parkinson's disease.. <i>Trends in Endocrinology and Metabolism</i> , <b>2021</b> ,	8.8	3
21	Alpha-synuclein supports interferon stimulated gene expression in neurons		3

20	Experimental colitis drives enteric alpha-synuclein accumulation and Parkinson-like brain pathology		3
19	Decreased Risk of Parkinson's Disease After Rheumatoid Arthritis Diagnosis: A Nested Case-Control Study with Matched Cases and Controls. <i>Journal of Parkinson's Disease</i> , <b>2021</b> , 11, 821-832	5.3	3
18	Optimizing maturity and dose of iPSC-derived dopamine progenitor cell therapy for Parkinson's disease.. <i>Npj Regenerative Medicine</i> , <b>2022</b> , 7, 24	15.8	3
17	Lots of Movement in Gut and Parkinson's Research. <i>Trends in Endocrinology and Metabolism</i> , <b>2019</b> , 30, 687-689	8.8	2
16	Mechanisms for cell-to-cell propagation no longer lag behind. <i>Movement Disorders</i> , <b>2016</b> , 31, 1798-1799	7	2
15	Direct targeting of wild-type glucocerebrosidase by antipsychotic quetiapine improves pathogenic phenotypes in Parkinson's disease models. <i>JCI Insight</i> , <b>2021</b> , 6,	9.9	2
14	An extended release GLP-1 analogue increases $\beta$ synuclein accumulation in a mouse model of prodromal Parkinson's disease. <i>Experimental Neurology</i> , <b>2021</b> , 341, 113693	5.7	2
13	Genetically engineered stem cell-derived neurons can be rendered resistant to alpha-synuclein aggregate pathology. <i>European Journal of Neuroscience</i> , <b>2019</b> , 49, 316-319	3.5	2
12	T cells limit accumulation of aggregate pathology following intrastriatal injection of $\beta$ synuclein fibrils		1
11	Alterations in odor hedonics in the 5XFAD Alzheimer's disease mouse model and the influence of sex.. <i>Behavioral Neuroscience</i> , <b>2020</b> , 134, 407-416	2.1	1
10	Prion-like transmission of protein aggregates in neurodegenerative diseases		1
9	Heterozygous GBA D409V and ATP13a2 mutations do not exacerbate pathological $\beta$ synuclein spread in the prodromal preformed fibrils model in young mice. <i>Neurobiology of Disease</i> , <b>2021</b> , 159, 105513	7.5	1
8	The roles of connectivity and neuronal phenotype in determining the pattern of $\beta$ synuclein pathology in Parkinson's disease.. <i>Neurobiology of Disease</i> , <b>2022</b> , 168, 105687	7.5	1
7	Methylated Cytochrome P450 and the Solute Carrier Family of Genes Correlate With Perturbations in Bile Acid Metabolism in Parkinson's Disease.. <i>Frontiers in Neuroscience</i> , <b>2022</b> , 16, 804261	5.1	0
6	Low plasma serotonin linked to higher nigral iron in Parkinson's disease.. <i>Scientific Reports</i> , <b>2021</b> , 11, 24384	4.9	0
5	Maternal Herpesviridae infection during pregnancy alters midbrain dopaminergic signatures in adult offspring.. <i>Neurobiology of Disease</i> , <b>2022</b> , 105720	7.5	0
4	Journal of Parkinson's disease. <i>Journal of Parkinson's Disease</i> , <b>2011</b> , 1, 1	5.3	
3	Future Cell- and Gene-Based Therapies for Parkinson's Disease <b>2008</b> , 145-156		

- 2 Alterations in odor hedonics in the 5XFAD Alzheimer's disease mouse model and the influence of sex. *Behavioral Neuroscience*, **2020**, 134, 407-416 2.1
- 1 Prion-Like Propagation in Neurodegenerative Diseases **2018**, 189-242